Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Vomiting 3Nausea 3Lymphoma 2Breast Neoplasms 2Vulvar Neoplasms 1Vulvar Diseases 1Uterine Cervical Dysplasia 1Sarcoma, Alveolar Soft Part 1Papillomavirus Infections 1Multiple Myeloma 1Lymphoma, Non-Hodgkin 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, Large B-Cell, Diffuse 1Inflammatory Breast Neoplasms 1Gynecologic Cancer 1Colonic Neoplasms 1Carcinoma in Situ 1Burkitt Lymphoma 1Breast Neoplasms, Male 1

Interventions

Surveys and Questionnaires 2Standard of Care 2Drug Therapy 2Brachytherapy 2genexol-PM 1gadobutrol 1fosaprepitant 1Therapeutics 1Surgical Procedures, Operative 1Sex 1Radiotherapy, Intensity-Modulated 1Psychotherapy 1Prochlorperazine 1Preoperative Exercise 1Population Groups 1Ondansetron 1Olanzapine 1Neurokinin-1 Receptor Antagonists 1NK Cell Lectin-Like Receptor Subfamily B 1Imagery, Psychotherapy 1FloSeal Matrix 1Ferric Oxide, Saccharated 1Exercise 1Enhanced Recovery After Surgery 1Educational Status 1Diagnostic Tests, Routine 1Diagnostic Imaging 1Dexamethasone 1Cryotherapy 1Counseling 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Gynecologic Cancer × Prochlorperazine × Clear all
NCT04503668 2025-06-18

Olanzapine for the Prevention of Chemotherapy Induced Nausea and Vomiting in Gynecologic Oncology Patients

University of Michigan Rogel Cancer Center

Phase 3 Terminated
62 enrolled 16 charts
Gynecologic

Gynecologic Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡